CLDN5 and Alzheimer disease: In D-galactose-mediated AD in rats, resveratrol (40 or 80 mg/kg body weight) inhibited Aβ1-42 fibril formation, neuroinflammation, accumulation of advanced glycation end-products (AGEs) and increased the integrity of the BBB (Claudin 5) indicating that in vivo, resveratrol can simultaneously alleviate neuroinflammation and oxidative stress in an AD model (Zhao et al., 2015).